Pfizer (PFE) is in focus after investors were hit with mixed oncology news, a planned CFO transition, and fresh questions around its pipeline, all set against the backdrop of patent expirations and restructuring efforts.

At a share price of $24.29, Pfizer has seen weaker momentum in recent months, with a 30 day share price return of 7.22% and a 90 day share price return of 12.53% despite oncology updates, legal clarity around Paxlovid, and a confirmed dividend. The 1 year total shareholder return of 7.43% contrasts with weaker 3 and 5 year total shareholder returns.

If oncology risk and pipeline news have you reassessing your watchlist, this could be a good moment to hunt for 39 healthcare AI stocks

With Pfizer offering a forward dividend yield near 7.1%, trading at a discount to some analyst targets, and screening with a high value score, investors must decide: is this a reset level, or is the market already pricing in future growth?

Most Popular Narrative: 13.3% Undervalued

Compared with Pfizer's last close at $24.29, the most followed narrative points to a fair value of $28.00, framing the current share price as a discount.

No final de 2025, a Pfizer Inc. (PFE) encontra-se em um momento pivotal de sua história. Após o boom extraordinário impulsionado pela vacina Comirnaty e pelo antiviral Paxlovid durante a pandemia, a empresa agora navega por águas mais calmas, e turbulentas. Os analistas de Wall Street, com um consenso geral de "Hold" e um preço-alvo médio em torno de US$ 28-30 para os próximos 12 meses (representando um upside modesto de 10-20% a partir dos níveis atuais próximos a US$ 25), veem a Pfizer como uma ação de valor defensiva, com alto dividend yield (acima de 6%), mas sem explosão de crescimento imediato.

According to Valrodmon, this fair value hangs on how Pfizer replaces maturing blockbusters with pipeline launches, cost cuts, and non COVID revenue trends. The moving parts are clear, but the exact growth, margin, and cash flow assumptions behind that $28.00 figure are not. That is where the narrative gets interesting.

Result: Fair Value of $28.00 (UNDERVALUED)

However, Pfizer's revenue and net income both declined year over year, and longer term total returns over 3 and 5 years remain weak, which can pressure sentiment.

Another View on Pfizer's Valuation

The first narrative frames Pfizer as 13.3% undervalued based on a fair value of $28.00, but the P/E picture is less clear cut. At 18.5x earnings, Pfizer trades above the US Pharmaceuticals industry average of 15.1x, yet below a peer average of 26.6x and close to a fair ratio of 18.9x. This points to less obvious upside and some valuation risk if sentiment turns.

For a closer look at how this earnings multiple compares with what the market could move towards, it is worth checking the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed signals around Pfizer's valuation, income profile, and pipeline can pull you in both directions, so move quickly, review the details, and weigh the 2 key rewards and 4 important warning signs.

Looking for more investment ideas beyond Pfizer?

If Pfizer has you rethinking your portfolio mix, do not stop there. Use focused stock lists to compare alternatives and sharpen your next move.

• Target potential mispricing by reviewing companies screened as 44 high quality undervalued stocks that may offer stronger value characteristics than what you currently hold.
• Strengthen your income stream by assessing stocks featured in the 8 dividend fortresses that align with your approach to yield and payout stability.
• Dial down volatility by filtering for companies in the 71 resilient stocks with low risk scores that better match your comfort with risk and capital preservation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.